FA
PSTX

Forefront Analytics’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Forefront Analytics’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,855
Closed -$79.7K – 71
2024
Q3 		$79.7K Sell
27,855
-1,962
-7% -$6.07K 0.04% 65
2024
Q2 		$87.1K Buy
29,817
+3,037
+11% +$8.31K 0.04% 64
2024
Q1 		$85.4K Buy
26,780
+1,311
+5% +$4.37K 0.04% 64
2023
Q4 		$85.6K Buy
25,469
+500
+2% +$1.29K 0.04% 61
2023
Q3 		$59.4K Sell
24,969
-1,650
-6% -$3.46K 0.03% 63
2023
Q2 		$46.9K Buy
26,619
+11,579
+77% +$29.6K 0.03% 64
2023
Q1 		$46.3K Sell
15,040
-230
-2% -$1.38K 0.02% 75
2022
Q4 		$80.9K Sell
15,270
-380
-2% -$1.74K 0.04% 61
2022
Q3 		$59K Sell
15,650
-7,720
-33% -$25.5K 0.03% 61
2022
Q2 		$61K Sell
23,370
-3,400
-13% -$9.45K 0.03% 59
2022
Q1 		$121K Buy
26,770
+16,150
+152% +$72.8K 0.04% 58
2021
Q4 		$72K Buy
10,620
+275
+3% +$1.87K 0.02% 59
2021
Q3 		$72K Buy
+10,345
New +$88.8K 0.03% 62

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Forefront Analytics's PSTX Position: Q4 2024 in Review

Forefront Analytics sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 27,855 shares — an estimated $79.7K sold.

Forefront Analytics first reported a position in PSTX in Q3 2021 and held it in 13 quarters. The position peaked at $121K in Q1 2022. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

  • Forefront Analytics reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Forefront Analytics sold 27,855 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $79.7K.
  • Forefront Analytics first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2021 and held it in 13 quarters.
  • Forefront Analytics's Poseida Therapeutics, Inc. Common Stock position peaked at $121K in Q1 2022.
  • 115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Forefront Analytics's 13F filing for Q4 2024, filed 14 Feb 2025.